Cardiol Therapeutics Announces AGM Results and New Board Member

An announcement from Cardiol Therapeutics ( (TSE:CRDL) ) is now available.

On May 28, 2025, Cardiol Therapeutics held its Annual General Meeting of Shareholders virtually, where all proposed management resolutions were approved. Notably, Dr. Timothy Garnett was elected as a new board member, bringing extensive pharmaceutical industry experience, which is expected to aid in advancing Cardiol’s strategic priorities, including ongoing clinical trials for CardiolRx™ in heart disease.

The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.

Spark’s Take on TSE:CRDL Stock

According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Underperform.

Cardiol Therapeutics faces substantial financial challenges, primarily driven by ongoing losses and negative cash flow. The stock’s technical indicators suggest mixed momentum, and its valuation is constrained by a negative P/E ratio. However, promising clinical developments and strategic advancements in heart disease treatments provide some positive outlook, though these are not sufficient to offset the financial and technical concerns.

To see Spark’s full report on TSE:CRDL stock, click here.

More about Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company’s lead product, CardiolRx™, is an oral solution of cannabidiol in clinical development for heart disease treatment. Cardiol is also working on CRD-38, a novel drug formulation for heart failure.

Average Trading Volume: 86,604

Technical Sentiment Signal: Sell

Current Market Cap: C$132.2M

Learn more about CRDL stock on TipRanks’ Stock Analysis page.